Exceptional Year-over-Year Growth for VYVGART
VYVGART achieved a 97% year-over-year growth across all approved indications, with 15,000 patients globally being treated, including 2,500 CIDP patients just one year into the launch.
Strong Financial Performance
Total operating income in Q2 2025 was $967 million, reflecting a 97% growth compared to the previous year, with $949 million in product net sales and a 19% quarter-over-quarter growth.
Global Market Expansion
VYVGART saw growth across all regions, with U.S. product net sales at $802 million, Japan at $52 million, and significant growth in Europe, Canada, and partner markets.
Introduction of Prefilled Syringe
The launch of the prefilled syringe has driven new patient starts and prescriber demand, with 50% of PFS patients being new to VYVGART.
Pipeline and Innovation Expansion
Advancing 4 new molecules into the pipeline, including ARGX-119, and collaborations to enhance capabilities, such as with Unnatural Products.